Compare BTMD & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | CING |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 64.6M |
| IPO Year | 2021 | N/A |
| Metric | BTMD | CING |
|---|---|---|
| Price | $2.17 | $5.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.83 | ★ $34.50 |
| AVG Volume (30 Days) | 199.3K | ★ 437.2K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $192,219,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $2.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $3.20 |
| 52 Week High | $4.75 | $11.89 |
| Indicator | BTMD | CING |
|---|---|---|
| Relative Strength Index (RSI) | 58.16 | 43.71 |
| Support Level | $2.02 | $4.94 |
| Resistance Level | $2.20 | $6.79 |
| Average True Range (ATR) | 0.12 | 0.48 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 54.15 | 40.42 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.